News | July 29, 2011

FDA Issues Draft Guidance on Device Changes Warranting New Premarket Review


July 29, 2011 — The U.S. Food and Drug Administration (FDA) this week issued draft guidance that clarifies when changes or modifications to a previously cleared 510(k) device require a new premarket submission.

The 510(k) process is the most common review path to market for lower-risk medical devices. To legally market a device, manufacturers must submit a premarket notification, or 510(k), demonstrating that the new or modified product is substantially equivalent to another legally marketed medical device. 

Manufacturers often make changes or modifications to a device after FDA clearance such as incorporating new technology or upgrading certain aspects of the device. Many changes do not require a 510(k) submission. But when the changes could significantly affect the product’s safety or effectiveness or constitute a major change to the intended use of the device, another 510(k) must be submitted.

“We are making the regulatory process for medical devices less challenging by better describing our expectations,” said Jeffrey Shuren, M.D., director of the FDA’s Center for Devices and Radiological Health. “In particular, manufacturers can continue to make innovative improvements to their devices and better plan for any updated submissions. This saves time and money.”

The draft guidance clarifies the kinds of changes that trigger the need for a new submission, such as specific kinds of labeling changes, changes to the technology used in the device, changes in performance specifications, manufacturing changes, and changes in the materials used in the manufacture of the device. 

This draft guidance is one of 25 action items listed in the FDA’s Plan of Action for Implementation of 510(k) and Science Recommendations launched in 2011 to enhance predictability, consistency, and transparency of the FDA’s premarket review programs. 

For more information: www.fda.gov


Related Content

News | Cardiac Imaging

March 18, 2026 — Circle Cardiovascular Imaging (Circle CVI) has announced the expansion of its cvi42 cardiovascular ...

Home March 20, 2026
Home
News | Cardiac Imaging

March 19, 2026 — Heart disease is the leading cause of adult death worldwide, making cardiovascular disease diagnosis ...

Home March 20, 2026
Home
News | Cardiac Imaging

March 16, 2026 — The American Society for Preventive Cardiology (ASPC) will host its 2026 Virtual Imaging Symposium, a ...

Home March 17, 2026
Home
Feature | Cardiac Imaging

Sponsored Content — According to the American Heart Association, cardiovascular disease is the leading cause of death in ...

Home March 13, 2026
Home
News | Cardiac Imaging

March 6, 2026 — Building on its leadership in cardiac MR, Philips has received FDA 510(k) clearance for SmartHeart, an ...

Home March 09, 2026
Home
News | Cardiac Imaging

Feb. 26, 2026 — The U.S. Food and Drug Administration (FDA) has given 510(k) class II clearance of qXR-Detect, the ...

Home February 26, 2026
Home
News | Cardiac Imaging

Feb. 13, 2026 — Conavi Medical Corp. recently highlighted the publication of new peer-reviewed research titled “Deep ...

Home February 16, 2026
Home
News | Cardiac Imaging

Jan. 27. 2026 — Circle Cardiovascular Imaging Inc. has announced the release of cvi42 v6.4, the latest version of its ...

Home January 28, 2026
Home
News | Cardiac Imaging

Jan. 6, 2026 — UltraSight, a provider of AI-guided cardiac imaging workflows, has announced FDA clearance to expand its ...

Home January 16, 2026
Home
News | Cardiac Imaging

Jan. 12, 2026 — YorLabs, Inc., a medical technology company providing next-generation intracardiac imaging solutions for ...

Home January 13, 2026
Home
Subscribe Now